Ahmad Danyal, Abira Nazir, Khalid Mahmood Qureshi, Roohi Manzoor Khan.
Hepatic insufficient patients; effect of alprazolam therapy on LFT`s.
Professional Med J Jan ;9(3):182-5.

The liver principally metabolizes Alprazolam. The effect of alprazolam therapy on LFT`s of fifteen hepatic insufficient patients, was assessed and compared with five control subjects. Alprazolam, in a dose of 0.25 mg, B.D., was given for 21 days to fifteen male and female patients, with age group from 24-42 years, having weight from 45-60 Kg, and compared with five control subjects. The mean values of direct bilirubin in control and hepatic insufficient patients were 0.25 mg% and 4.71 mg% on day zero, while on day 21, the values were 0.52 mg% and 4.42 mg%, respectively. Total bilirubin was 0.76 mg% and 6.28 mg% on day zero and 0.53 mg% and 5.54 mg% on day 21 in control and hepatic insufficient patients, respectively. The mean values of alkaline phosphatase (ALP) were 154.50 U/L on day zero and 169.20 U/L on day 21 in control group, while these were 626.40 U/L on day zero and 677.70 U/L on day 21, in hepatic insufficient patients. The mean values of serum glutamic pyruric transaminase (SGPT) were 26 U/L on day zero and 27.40 U/L on day 21 in control group, while these were 48.0 U/L and 60.60 U/L on day 21 in hepatic insufficient patients. From above data, it was concluded that long-term alprazolam therapy have no effect on direct and total bilirubin but the values of ALP and SGPT increased.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com